ID
42247
Beschrijving
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS. https://clinicaltrials.gov/ct2/show/NCT00391872
Link
https://clinicaltrials.gov/ct2/show/NCT00391872
Trefwoorden
Versies (3)
- 28-11-15 28-11-15 -
- 14-04-21 14-04-21 - Ahmed Rafee, MD
- 15-04-21 15-04-21 - Ahmed Rafee, MD
Houder van rechten
AstraZeneca
Geüploaded op
15 april 2021
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Excerpt PLATO Acute coronary Syndrome NCT00391872
Section Investigational Products
Similar models
Section Investigational Products
C1608718 (UMLS CUI [1,2])
C1608718 (UMLS CUI [1,2])
C0070166 (UMLS CUI [1,2])
C0070166 (UMLS CUI [1,2])
Geen commentaren